Andrzej Maćkiewicz - Concepedia

Author

Andrzej Maćkiewicz

Also Known As

A Mackiewicz, A. MACKIEWICZ, A. Mackiewicz, ANDRZEJ MACKIEWICZ, Andrzej A. Mackiewicz, Andrzej Adam Mackiewicz, Andrzej MACKIEWICZ, Andrzej Mackiewicz, Andrzej Maćkiewicz, Aneta Maćkiewicz

338

Publications

25.3K

Citations

H-Index

201

Concepts

All Affiliations

Greater Poland Cancer Center Poznan University of Medical Sciences The Maria Sklodowska-Curie National Research Institute of Oncology Medical University of Warsaw Adam Mickiewicz University in Poznań

About

Andrzej Maćkiewicz is an author at Greater Poland Cancer Center specializing in medicine, immunology, and immunotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	29	51	6.7K
2	Engineering	9	9	1.8K
3	Health Sciences	8	9	789
4	Natural Sciences	2	2	106
5	Public Health	1	1	86

Andrzej Maćkiewicz

118

Publications

15.3K

Citations

H-Index

Page 1

	Year	Citations
Genomic Classification of Cutaneous Melanoma Rehan Akbani, Kadir C. Akdemir, Bülent Arman Aksoy, Cell Dermoscopic ImageSkin CancerMedicineMelanomaPathology	2015	3.2K
Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib Caroline Robert, Bogusława Karaszewska, Jacob Schachter, New England Journal of Medicine	2014	2.6K
Principal components analysis (PCA) Andrzej Maćkiewicz, Waldemar Ratajczak Computers & Geosciences EngineeringData ScienceData MiningMultidimensional AnalysisPrincipal Components Analysis	1993	1.5K
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma Caroline Robert, Jean‐Jacques Grob, Daniil Stroyakovskiy, New England Journal of Medicine	2019	1.3K
The soluble interleukin‐6 receptor is generated by shedding Jürgen Mülberg, Heidi Schooltink, Tanja Stoyan, European Journal of Immunology	1993	509
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial Paolo A. Ascierto, Michele Del Vecchio, Caroline Robert, The Lancet Oncology MedicineMelanomaIpilimumab 10Clinical TrialsMetastatic Melanoma	2017	483
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins Andrzej Maćkiewicz, Heidi Schooltink, Peter C. Heinrich, The Journal of Immunology	1992	375
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial Jean‐Jacques Grob, Mayur M. Amonkar, Bogusława Karaszewska, The Lancet Oncology MedicineMelanomaClinical TrialsPharmacotherapyDermatology	2015	255
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial Michele Maio, Karl D. Lewis, Lev Demidov, The Lancet Oncology MedicineMelanomaImmunologyClinical TrialsAdjuvant Vemurafenib	2018	210

Page 1